Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mda-5 siRNA
- Development stage
- Preclinical
- Lead developer
- The Ohio State University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Parenteral
01
Overview
MDA-5 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the melanoma differentiation-associated protein 5 (MDA-5), also known as interferon induced with helicase C domain 1 (IFIH1). MDA-5 is a cytosolic pattern recognition receptor that detects double-stranded RNA (dsRNA) and triggers innate immune responses. In the context of pulmonary arterial hypertension (PAH) research, MDA-5 siRNA has been used to demonstrate that loss of MDA-5 signaling in pulmonary artery endothelial cells (PAECs) leads to increased apoptosis and impaired cellular homeostasis, contributing to the pathogenesis of pulmonary hypertension. This agent is primarily used as a research tool in molecular biology and experimental pathology to investigate the MDA-5/IL-10RA signaling axis.
- Other names
- siRNA targeting MDA-5IFIH1 siRNAIFIH-1 siRNAIFIH 1 siRNAmelanoma differentiation-associated protein 5 siRNA
02
Targets
IFIH1 (MDA5)
Beyond the preview
Go deeper on mda-5 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mda-5 siRNA.